Roche: to present updated data on liver cancer drug

(CercleFinance.com) - This weekend, Roche will showcase updated data confirming that Tecentriq, in combination with Avastin, substantially improves survival in patients with the most common form of liver cancer.


At a meeting of the the American Society of Clinical Oncology (ASCO) next Sunday, Roche researchers will present data from a Phase III study evaluating the combo, compared with Bayer's sorafenib, in people with unresectable hepatocellular carcinoma who have not received prior systemic therapy.

After a median follow-up of 15.6 months, the updated analysis showed that Tecentriq, in combination with Avastin, cut the risk of death by 34%, with a median overall survival of 19.2 months, compared with 13.4 months for sorafenib, Roche said.

This is the longest survival ever seen in a front-line Phase III study in unresectable hepatocellular carcinoma, the drugmaker noted.

Tecentriq in combination with Avastin is already approved for people with liver cancer in many countries around the world, including the US, China, Japan and the EU.

Copyright (c) 2021 CercleFinance.com. All rights reserved.